|
Phase III Clinical Trial Update and New IIH Market Analysis
|
28 June 2023 at 9:10am
|
|
Invex Granted European Orphan Drug Designation for TBI
|
23 June 2023 at 8:40am
|
|
Invex Receives Regulatory Approval for IIH EVOLVE in France
|
21 April 2023 at 8:40am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
20 April 2023 at 9:15am
|
|
Israel Ministry of Health Approval for IIH EVOLVE
|
20 April 2023 at 8:35am
|
|
March Appendix 4C and Investor Conference Call Details
|
17 April 2023 at 5:55pm
|
|
Notification of cessation of securities - IXC
|
12 April 2023 at 2:00pm
|
|
German Approval for IIH EVOLVE Phase 3 Clinical Trial
|
20 March 2023 at 8:35am
|
|
Publication of Invex IIH Phase II Pressure Trial Results
|
14 March 2023 at 8:35am
|
|
Half Year Accounts
|
17 February 2023 at 10:10am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
25 January 2023 at 9:00am
|
|
Notification of cessation of securities - IXC
|
23 January 2023 at 12:25pm
|
|
Notice of Quarterly Investor Call
|
19 January 2023 at 10:30am
|
|
First US Clinical Site Activated in IIH EVOLVE Phase III
|
19 January 2023 at 9:55am
|
|
Invex Receives Approval for Paediatric Plan from the EMA
|
14 December 2022 at 9:30am
|
|
Update - Notification regarding unquoted securities - IXC
|
8 December 2022 at 4:40pm
|
|
Change of Director's Interest Notice x 4
|
7 December 2022 at 3:50pm
|
|
Notification regarding unquoted securities - IXC
|
5 December 2022 at 1:10pm
|
|
Invex to Present at the MST Financial Biotech Forum
|
30 November 2022 at 2:10pm
|
|
MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ
|
25 November 2022 at 10:25am
|
|
Investor Presentation
|
22 November 2022 at 1:30pm
|
|
Results of Meeting
|
22 November 2022 at 1:30pm
|
|
AGM Presentation
|
22 November 2022 at 12:00pm
|
|
AGM Chairmans Address
|
22 November 2022 at 11:55am
|
|
First Patient Randomised in IIH EVOLVE Phase III Trial
|
21 November 2022 at 8:40am
|
|
Invex Receives $0.46 Million R&D Tax Rebate
|
1 November 2022 at 9:15am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 October 2022 at 8:40am
|
|
Upcoming Presentation at Argonaut Biotech Briefing
|
26 October 2022 at 2:00pm
|
|
September Appendix 4C and Investor Conference Call Details
|
24 October 2022 at 12:40pm
|
|
First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial
|
24 October 2022 at 9:50am
|
|
First Australian Site Activated in IIH EVOLVE Phase 3
|
24 October 2022 at 8:40am
|
|
Notice of Annual General Meeting/Proxy Form
|
21 October 2022 at 12:50pm
|
|
Second HREC Approval for IIH EVOLVE Phase III Clinical Trial
|
30 September 2022 at 9:15am
|
|
Date of AGM and Director Nominations
|
23 September 2022 at 11:05am
|
|
Invex to Present at Virtual ASX Small and Mid-Cap Conference
|
12 September 2022 at 8:35am
|
|
Appendix 4G
|
19 August 2022 at 10:20am
|
|
Corporate Governance Statement
|
19 August 2022 at 10:20am
|
|
4E and Annual Report to shareholders
|
19 August 2022 at 10:05am
|
|
Invex receives IND approval
|
19 August 2022 at 9:50am
|
|
Trading Halt
|
18 August 2022 at 10:00am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
6 July 2022 at 10:20am
|
|
HREC and TGA Approval to Commence Phase 3 in Australia
|
4 July 2022 at 9:10am
|
|
Appendix 4C and Investor Conference Call Details
|
1 July 2022 at 11:30am
|
|
Invex Receives UK Approval to Commence Phase III Trial
|
29 June 2022 at 8:55am
|
|
Upcoming Presentations to the 15th EUNOS Meeting
|
20 June 2022 at 10:59am
|
|
Invex to Present at Aerospace Medical Association Meeting
|
20 May 2022 at 8:55am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
19 April 2022 at 9:10am
|
|
March Appendix 4C and Investor Conference Call Details
|
13 April 2022 at 10:05am
|
|
Executive Director Agreement
|
1 April 2022 at 4:10pm
|
|
Invex to Present at Upcoming Tech Biotech Broker Briefing
|
22 March 2022 at 9:20am
|
Invex Therapeutics Ltd